Medifocus Inc. is in the business of developing and selling medical device systems that deliver precisely focused, microwave-generated heat to diseased tissue, thereby destroying or shrinking it. The Company owns over three technology platforms. The Endo-thermotherapy Platform is a catheter-based focused heat technology platform that utilizes natural body openings to deliver microwave thermotherapy to the diseased sites. The Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia was developed based on the Endo-thermotherapy Platform. The Adaptive Phased Array (APA) Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy Technology is used for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases.
Industry, Sector and Symbol:
- Market Cap: C$7.4 million
- Outstanding Shares: 184,984,000
- 52 Week Range: C$0.01 - C$0.05
Sales & Book Value:
- Trailing P/E Ratio:
- P/E Growth:
- Annual Revenue: C$3.31 million
- Price / Sales: 2.24
- Book Value: C($0.05) per share
- Price / Book: -0.80
- EBIDTA: ($110,964.00)
- Net Margins: -31.84%
- Return on Assets: -25.38%
- Average Volume: 15,446 shs.
Frequently Asked Questions for Medifocus (CVE:MFS)
What is Medifocus' stock symbol?
Medifocus trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MFS."
When will Medifocus make its next earnings announcement?
Who are some of Medifocus' key competitors?
Some companies that are related to Medifocus include Crown Point Energy (CWV), Champion Bear Resources (CBA), New Zealand Energy Corp (NZ), Oceanic Iron Ore Corp (FEO), Silverwillow Energy Corp (SWE), North American Tungsten Co. Ltd (NTC), Alderon Iron Ore Corp (ADV), Arcan Resources (ARN), Ceiba Energy Services (CEB), CRH Medical Corp (CRM), Donnycreek Energy (DCK), Elgin Mining (ELG), Esperanza Resources Corp (EPZ), Grenville Strategic Royalty Corp (TVN.H), GrowMax Resources Corp (BOE), Hana Mining Ltd (HMG), Hyperion Exploration Corp (HYX) and Integra Gold Corp (ICG).
Who are Medifocus' key executives?
Medifocus' management team includes the folowing people:
- Grant B. Walsh, Chairman of the Board
- William W. Jow M.D., Chief Executive Officer, Director
- Mirsad Jakubovic, Chief Financial Officer
- John Mon, Chief Operating Officer
- Raymond Tong, Director
- Shuen Chuen Chan, Independent Director
- Augustine Pok Yu Chow Ph.D., Independent Director
- Tak Cheung Yam, Independent Director
How do I buy Medifocus stock?
Shares of Medifocus and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Medifocus' stock price today?
MarketBeat Community Rating for Medifocus (CVE MFS)MarketBeat's community ratings are surveys of what our community members think about Medifocus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Medifocus stock can currently be purchased for approximately C$0.04.
Consensus Ratings for Medifocus (CVE:MFS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Medifocus (CVE:MFS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Medifocus (CVE:MFS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Medifocus (CVE:MFS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Medifocus (CVE:MFS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Medifocus (CVE:MFS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Medifocus (CVE:MFS)
Latest Headlines for Medifocus (CVE:MFS)
No headlines for this company have been tracked by MarketBeat.com
Medifocus (MFS) Chart for Friday, September, 22, 2017